A Dose-response Study With Strontium Malonate in Postmenopausal Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

275 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to compare dose-response effect of three dose levels of strontium malonate to placebo on bone resorption quantified by S-CTX-1 following 12 weeks of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

NCT04757376

Postmenopausal Women With Osteoporosis

COMPLETED PHASE3

Intervention Study of Drugs in Patients Osteopenia and Osteoporosis

NCT04719572

Osteoporosis Osteopenia, Osteoporosis

UNKNOWN NA

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

NCT01631214

Postmenopausal Women With Osteoporosis

COMPLETED PHASE3

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244

Osteoporosis

COMPLETED PHASE3

Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis

NCT00404820

Osteoporosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

275 post menopausal women are treated with either 750 mg strontium malonate, 1000 mg strontium malonate, 2000 mg strontium malonate, 2 g Protelos® or placebo.

Patients are treated for 12 weeks. A follow up period of 4 weeks is planned for the main study and a follow up period of 8 weeks is planned for approximately 20% of the patients to follow post treatment CTX-1 activity.

Apart from S-CTS-1 also response on other bio markers are evaluated as well as BMD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Strontium malonate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women (at least 12 months since last menstruation).
* BMD (L2-4) T-score between -1 and -3 (at least 20% of the enrolled patients must have a BMD (L2-4) T-score below -2,5).
* 50 years of age.
* BMI\<30 kg/m2.
* Total S-Ca level within normal range.
* Ability to read and understand the information given.
* The patient has signed an informed consent form according to ICH E6 and local requirements before any study specific procedure is carried out.
* Ability to comply with study procedures.

Exclusion Criteria

* History of prior fragility fracture (any fracture in wrist, hip or spine appearing after 40 years of age).
* History of alcohol or drug abuse.
* Metabolic bone disease (e.g. pagets disease, bone cancer).
* History of VTE/DVT.
* History of kidney transplant.
* Bilateral oophorectomy.
* Relevant and treated reduced kidney or liver function.
* Any malignancy within the last 5 years (except basal cell carcinoma)
* Any chronic condition likely to affect absorption (e.g. Crohns disease, gluten enteropathy).
* Known genetic pre-disposition to VTE/DVT
* Known hypersensitivity to any of the active substances or excipients.
* 25-OH-vitamin D level below 25 nmol/L
* Any previous treatment with bisphosphonates, Strontium or fluoride.
* Treatment during the last 3 months affecting calcium balance or bone metabolism (e.g. thiazides, corticosteroids, calcitonin, HRT, SERMs, PTH, phosphorus).
* Treatment during the last week with tetracycline, ciprofloxacin or loop diuretics.
* PTH out of normal range
* Use of any drug known to influence the coagulation process (aspirin and other NSAID allowed)
* Prothrombin time out of normal range (sec or INR)
* Inclusion in another clinical study within 30 days before randomization or during this study

Minimum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No